Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Hem/Onc > Lung Cancer > Flashcards

Lung Cancer Flashcards

1
Q

Alecensa

A

alectinib
ALK inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Xalkori

A

crizotinib
ALK inhibitor
ROS1 inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Zykadia

A

ceritinib
ALK inhibitor
ROS1 inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Alunbrig

A

brigatinib
ALK inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Lorbrena

A

lorlatinib
ALK inhibitor
ROS1 inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Rozlytrek

A

entrectinib
ROS1 inhibitor
NTRK inhibitor- pan tumor indication

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Lumakras

A

Sotorasib
KRAS G12C inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Tarceva

A

Erlotinib
EGFR inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Gilotrif

A

Afatinib
EGFR inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Iressa

A

Gefitinib
EGFR inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Tagrisso

A

Osimertinib
EGFR inhibitor
Effective against T790M mutation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Vizimpro

A

Dacomitinib
EGFR inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Drugs for Exon 20 Insertion Mutation (2)

A

Rybrevant (Amivantamab) IV
BISPECIFIC EGFR/MET target ADCC

Exkivity (Mobocertinib) PO

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Portrazza

A

Necitumumab (IV)
EGFR inhibitor for squamous cell NSCLC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Tafinlar + Mekinist

A

Tafinlar (Dabrafinib)- BRAF inhibitor
Mekinist (Trametinib) MEK inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Retevmo

A

Selpercatinib

Indications
NSLC - RET fusion
MTC - RET mutation
Thyroid Cancer - RET fusion
Solid tumors with RET fusion

< 50 kg 120 MG twice daily
> 50 kg 160 MG twice daily

HHH coughing up a cutie
TLS
Impaired wound healing (VEGF)

17
Q

Gavreto

A

Pralsetinib

Same indications as Retevmo EXCEPT no pan-tumor indication

400 MG once daily on an empty stomach

No QT warning

18
Q

Tabrecta

A

Capmatinib
MET inhibitor

19
Q

Tepmetko

A

Tepotinib
MET inhibitor
MET exon 14 skipping alterations

Hem/Onc (16 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions